Search Results - "Johansen, Lene E"

Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer by Alves, Carla L., Ehmsen, Sidse, Terp, Mikkel G., Portman, Neil, Tuttolomondo, Martina, Gammelgaard, Odd L., Hundebøl, Monique F., Kaminska, Kamila, Johansen, Lene E., Bak, Martin, Honeth, Gabriella, Bosch, Ana, Lim, Elgene, Ditzel, Henrik J.

“…CDK4/6 inhibitors (CDK4/6i) combined with endocrine therapy have shown impressive efficacy in estrogen receptor-positive advanced breast cancer. However, most…”
Get full text

Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer by Alves, Carla L., Ehmsen, Sidse, Terp, Mikkel G., Portman, Neil, Tuttolomondo, Martina, Gammelgaard, Odd L., Hundebøl, Monique F., Kaminska, Kamila, Johansen, Lene E., Bak, Martin, Honeth, Gabriella, Bosch, Ana, Lim, Elgene, Ditzel, Henrik J.

Get full text

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer by Al-Qasem, Abeer J., Alves, Carla L., Ehmsen, Sidse, Tuttolomondo, Martina, Terp, Mikkel G., Johansen, Lene E., Vever, Henriette, Hoeg, Luna V. A., Elias, Daniel, Bak, Martin, Ditzel, Henrik J.

“…Resistance to aromatase inhibitor (AI) treatment and combined CDK4/6 inhibitor (CDK4/6i) and endocrine therapy (ET) are crucial clinical challenges in treating…”
Get full text

Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER‐positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor by Karimi, Leena, Alves, Carla L., Terp, Mikkel G., Tuttolomondo, Martina, Portman, Neil, Ehmsen, Sidse, Johansen, Lene E., Bak, Martin, Lim, Elgene, Ditzel, Henrik J.

“…List of abbreviations CDK4/6 Cyclin-dependent kinase 4/6 CDK4/6i CDK4/6-inhibitor ER Estrogen receptor ERBB2 Erb-B2 receptor tyrosine kinase 2 ES Enrichment…”
Get full text

MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit by Løkkegaard, Sanne, Elias, Daniel, Alves, Carla L., Bennetzen, Martin V., Lænkholm, Anne-Vibeke, Bak, Martin, Gjerstorff, Morten F., Johansen, Lene E., Vever, Henriette, Bjerre, Christina, Kirkegaard, Tove, Nordenskjöld, Bo, Fornander, Tommy, Stål, Olle, Lindström, Linda S., Esserman, Laura J., Lykkesfeldt, Anne E., Andersen, Jens S., Leth-Larsen, Rikke, Ditzel, Henrik J.

“…Resistance to endocrine therapy in estrogen receptor-positive (ER + ) breast cancer is a major clinical problem with poorly understood mechanisms. There is an…”
Get full text

Discriminating Isogenic Cancer Cells and Identifying Altered Unsaturated Fatty Acid Content as Associated with Metastasis Status, Using K-Means Clustering and Partial Least Squares-Discriminant Analysis of Raman Maps by Hedegaard, Martin, Krafft, Christoph, Ditzel, Henrik J, Johansen, Lene E, Hassing, Søren, Popp, Jürgen

“…Raman spectroscopy is a label-free, real-time diagnostic tool that shows great promise in identifying cell differences. We have evaluated the discriminatory…”
Get full text

Identification of genes with altered expression in medullary breast cancer vs. ductal breast cancer and normal breast epithelia by GJERSTORFF, Morten F, BENOIT, Vivian M, LAENKHOLM, Anne-Vibeke, NIELSEN, Ole, JOHANSEN, Lene E, DITZEL, Henrik J

“…Medullary breast cancer (MCB) is a morphologically and biologically distinct subtype that, despite cytologically highly malignant characteristics, has a…”
Get full text